Drug Profile

PMN 310

Alternative Names: huPMN-310; PMN-310

Latest Information Update: 07 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProMIS Neurosciences
Class Antidementias; Monoclonal antibodies; Neuroprotectants
Mechanism of Action Amyloid beta-protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Alzheimer's disease

Most Recent Events

13 Dec 2024 ProMis Neurosciences initiates enrolment in the phase I PRECISE-AD trial for Alzheimer's disease in the US (IV) (NCT06750432)
30 Oct 2024 Adverse events and pharmacokinetics data from the phase Ia trial in Alzheimer's disease released by ProMIS Neurosciences
19 Sep 2024 ProMIS Neurosciences completes a phase-I trial in Alzheimer's disease (In volunteers) in USA (IV) (NCT06105528)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com